Abstracts

PHASE I/II STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AVELUMAB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Jibran Ahmed*, Anne Kriksite, Bette Stephen, Yali Yang, Juhee Song, Anas Alshawwa, Abdulrazak Zarifa, Van Morris, Milind Javle, Robert A Wolff, Funda Meric-Bernstam, Shubham Pant, Jordin Rodon, Aung Naing. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background

Checkpoint agonists OX40 and 4-1BB can augment the effector function of T cells in cancers, which is counterbalanced by the upregulation of programmed death-ligand 1 (PD-L1) on cancer cells. Preclinical studies suggest that combining utomilumab (4-1BB agonist) and ivuxolimab (OX40 agonist) with avelumab (an anti-PD-L1 monoclonal antibody) can potentially synergize to enhance T cell function and simultaneously overcome the effects of upregulation of PD-L1 resulting in clinical benefit. Additionally, the tissue abscopal effect of radiation therapy can improve antigen presentation and complement PD-L1 blockade. Therefore, we conducted a single institution, open-label, multi-arm, non-randomized, phase 1/2 clinical trial of avelumab in combination with utomilumab, ivuxolimab or radiation therapy in patients with advanced cancer. (Clinicaltrial.gov identifier NCT03217747)

Methods

We present a subgroup analysis in patients with gastrointestinal (GI) tumors (pancreatic, colon, gastric and hepatocellular (HCC)). The study arms included: Arm B with utomilumab plus ivuxolimab; Arm C with utomilumab plus ivuxolimab and ivuxolimab; Arm E with avelumab and ivuxolimab plus radiation therapy; And arm F with avelumab, utomilumab and ivuxolimab plus radiation therapy. The primary objectives of this study were to establish safety, tolerability and dose-limiting toxicities of these treatment combinations and the secondary objectives were to evaluate efficacy including response rate, progression free survival, and overall survival.

Results

Thirty-one patients with pancreatic (n=21), colorectal (n=8), HCC (n=1) and gastric (n=1) cancers were included in this study. The most common treatment-related adverse events (TRAEs) were chills (12.9%), diarrhea (9.7%), colitis (9.7%), fatigue (6.5%), and fever (6.5%). There were 3 instances of grade 3 diarrhea and colitis each (9.7%) without any other treatment related grade 3, 4 or 5 AEs based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Among the 24 patients evaluable for response, 9 (37.5%) had immune-related stable disease (irSD) and 14 (58.3%) had immune-related progressive disease (irPD) by immune related Response Evaluation Criteria in Solid Tumors (irRECIST). One patient had clinical progression of disease. The median progression free survival (mPFS) was 2 months per irRECIST and the median overall survival (mOS) was 5.6 months. Correlative studies are ongoing.

Conclusions

Combining immune checkpoint inhibitors with checkpoint agonists produces modest activity without added safety concerns in patients with advanced GI malignancies. The findings from this study can provide insights for future investigations in this field of research.

Acknowledgements

The authors wish to thank the patients and their families and caregivers for participating in the study. The authors also thank Pfizer, Inc. for financial and material support of this study. This study was supported in part by the NIH CCSG Award (P30CA016672). Study drugs were provided by Pfizer, as part of an alliance between Pfizer and the healthcare business of Merck KGaA, Darmstadt, Germany. (CrossRef Funder ID: 10.13039/100009945)

Trial Registration

NCT03217747

REFERENCES


Ethics Approval

The protocol was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center. This study was conducted in accordance with current U.S. Food and Drug Administration (FDA) regulations, Good Clinical Practice (GCP), the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, the ethical principles stated in the Declaration of Helsinki, and all local ethical and legal requirements.

Consent

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

http://dx.doi.org/10.1136/jitc-2023-SITC2023.0584